## Venezuela (Bolivarian Republic of)

### Population 2018

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate per 100,000 population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total TB incidence</strong></td>
<td>14 (11–17)</td>
<td>48 (37–60)</td>
</tr>
<tr>
<td><strong>HIV-positive TB incidence</strong></td>
<td>1.2 (0.41–2.5)</td>
<td>4.2 (1.4–8.6)</td>
</tr>
<tr>
<td><strong>MDR/RR-TB incidence</strong></td>
<td>0.4 (0.15–0.77)</td>
<td>1.4 (0.52–2.7)</td>
</tr>
<tr>
<td><strong>HIV-negative TB incidence</strong></td>
<td>0.73 (0.69–0.78)</td>
<td>2.5 (2.4–2.7)</td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td>0.27 (0.088–0.55)</td>
<td>0.94 (0.3–1.9)</td>
</tr>
</tbody>
</table>

### TB case notifications, 2018

- **Number (thousands)**: 11,017
- **% tested with rapid diagnostics at time of diagnosis**: 58%
- **% with known HIV status**: 58%
- **% pulmonary**: 87%
- **% bacteriologically confirmed**: 76%
- **% children aged 0–14 years**: 6%
- **% women**: 30%
- **% men**: 64%

### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2018**: 80% (63–100)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 7% (5–10)
- **TB/HIV care in new and relapse TB patients, 2018**:
  - Number: 473
  - % on antiretroviral therapy: 300

### Drug-resistant TB care, 2018

- **% of bacteriologically confirmed TB cases tested for rifampicin resistance**: 
  - New cases: 6%
  - Previously treated cases: 44%

### Treatment success rate and cohort size

- **New and relapse cases registered in 2017**: 82% (10,647)
- **Previously treated cases, excluding relapse, registered in 2017**: 74% (305)
- **HIV-positive TB cases registered in 2017**: 88% (528)
- **MDR/RR-TB cases started on second-line treatment in 2016**: 72% (57)
- **XDR-TB cases started on second-line treatment in 2016**: 0

### TB preventive treatment, 2018

- **% of HIV-positive people (newly enrolled in care) on preventive treatment**: 2%
- **% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment**: 96% (71–100)

### TB financing, 2019

- **National TB budget (US$ millions)**: 2.7
  - Funding source: 21% domestic, 0% international, 79% unfunded

---

* Ranges represent uncertainty intervals

MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

** Calculated for pulmonary cases only

Includes cases with unknown previous TB treatment history

Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-03-04

Data: www.who.int/tb/data